Actinium Pharmaceuticals, Inc. (ATNM) shareholders
Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ATNM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,238,302 | 3.94% | $1.21M | −17,214 | 0.00% |
| Compass Financial Management LLC | 600,230 | 1.91% | $588.23K | New | 0.07% |
| Millennium Management LLC | 514,580 | 1.64% | $504.29K | −50,020 | 0.00% |
| Acadian Asset Management LLC | 496,288 | 1.58% | $485.00K | −104,531 | 0.00% |
| BlackRock, Inc. | 395,896 | 1.26% | $387.98K | +24,686 | 0.00% |
| Renaissance Technologies LLC | 380,491 | 1.21% | $372.88K | −91,109 | 0.00% |
| Geode Capital Management, LLC | 324,945 | 1.03% | $318.55K | −11,128 | 0.00% |
| Two Sigma Investments, LP | 259,179 | 0.82% | $254.00K | −77,989 | 0.00% |
| Gagnon Securities LLC | 182,142 | 0.58% | $178.50K | −19,158 | 0.03% |
| Vanguard Fiduciary Trust Co | 161,526 | 0.51% | $158.30K | +1,261 | 0.00% |
| State Street Corp | 122,215 | 0.39% | $119.77K | −4,000 | 0.00% |
| Gen-Wealth Partners Inc | 105,111 | 0.33% | $103.01K | −2,000 | 0.03% |
| Northern Trust Corp | 69,743 | 0.22% | $68.35K | −6,112 | 0.00% |
| Qube Research & Technologies Ltd | 57,812 | 0.18% | $56.66K | +39,764 | 0.00% |
| Susquehanna International Group, Llp | 56,822 | 0.18% | $55.69K | −67,176 | 0.00% |
| Vontobel Holding Ltd. | 50,000 | 0.16% | $49.00K | +20,000 | 0.00% |
| SNS Financial Group, LLC | 43,000 | 0.14% | $42.14K | New | 0.00% |
| Bridgeway Capital Management, LLC | 40,000 | 0.13% | $39.20K | – | 0.00% |
| Am Investment Strategies LLC | 29,356 | 0.09% | $29.00K | – | 0.00% |
| Gerald Baker Financial Group LLC | 22,691 | 0.07% | $22.24K | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 47 | 5M | 16.8% | 6 / 6 | 20 / 12 | 1M | 1M |
| Q1 2026 | 54 | 5M | 16.9% | 7 / 12 | 14 / 12 | 2M | 1M |
| Q4 2025 | 60 | 5M | 17.2% | 9 / 13 | 19 / 8 | 1M | 0M |
| Q3 2025 | 61 | 5M | 16.4% | 9 / 9 | 29 / 10 | 1M | 1M |
| Q2 2025 | 63 | 5M | 17.4% | 19 / 11 | 22 / 25 | 2M | 4M |
| Q1 2025 | 69 | 8M | 26.1% | 10 / 24 | 17 / 9 | 1M | 1M |
| Q4 2024 | 69 | 8M | 25.9% | 14 / 27 | 14 / 17 | 1M | 1M |
| Q3 2024 | 72 | 8M | 26.9% | 17 / 24 | 19 / 18 | 4M | 1M |
| Q2 2024 | 74 | 7M | 23.1% | 19 / 27 | 17 / 11 | 1M | 1M |
| Q1 2024 | 67 | 7M | 21.9% | 13 / 19 | 17 / 4 | 1M | 0M |
| Q4 2023 | 59 | 6M | 18.7% | 7 / 18 | 18 / 6 | 0M | 0M |
| Q3 2023 | 58 | 6M | 18.3% | 4 / 21 | 11 / 16 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
11 funds held ATNM in Q2 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ATNM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 918,557 | 2.92% | $900.19K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 315,369 | 1.00% | $309.06K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 171,447 | 0.55% | $216.02K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 106,723 | 0.34% | $104.59K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 52,287 | 0.17% | $65.88K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 44,530 | 0.14% | $56.11K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 40,000 | 0.13% | $39.20K | 0.03% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 5,849 | 0.02% | $5.73K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 4,376 | 0.01% | $4.29K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 3,114 | 0.01% | $3.05K | 0.00% | Jun 30, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 175 | 0.00% | $146 | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sandesh Seth | Chief Executive Officer, Director | 938,081 | 2.98% | Sep 4, 2026 |
| Matthew T. David | Chief Financial Officer | 250,000 | 0.80% | Oct 16, 2026 |
| Adeela Kamal | Chief Scientific Officer | 213,648 | 0.68% | Sep 10, 2026 |
| Steffen Wilhem Heeger | Chief Medical Officer | 153,868 | 0.49% | Sep 10, 2026 |
| Steve O'Loughlin | Chief Financial Officer | 35,500 | 0.11% | Apr 2, 2025 |
| Richard I. Steinhart | Director | 63,116 | 0.20% | Sep 4, 2026 |
| Nicholson, C. David | Director | 63,300 | 0.20% | Sep 4, 2026 |
| June Sherie Almenoff | Director | 18,000 | 0.06% | Sep 4, 2026 |
| Ajit Shetty | Director | 62,357 | 0.20% | Sep 4, 2026 |
| Jeffrey W. Chell | Director | 61,600 | 0.20% | Sep 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew T. David Chief Financial Officer | Oct 14, 2026 | Award | +250,000 | – | – | 250,000 |
| Sandesh Seth Chief Executive Officer, Director | Sep 2, 2026 | Award | +753,600 | – | – | 938,081 |
| Sandesh Seth Chief Executive Officer, Director | Sep 2, 2026 | Award | +1,027,274 | – | – | 1,965,355 |
| June Sherie Almenoff Director | Sep 2, 2026 | Award | +18,000 | – | – | 18,000 |
| Nicholson, C. David Director | Sep 2, 2026 | Award | +62,800 | – | – | 63,300 |
| Richard I. Steinhart Director | Sep 2, 2026 | Award | +62,800 | – | – | 63,116 |
| Ajit Shetty Director | Sep 2, 2026 | Award | +61,600 | – | – | 62,357 |
| Jeffrey W. Chell Director | Sep 2, 2026 | Award | +61,600 | – | – | 61,600 |
| Sandesh Seth Chief Executive Officer, Director | Aug 18, 2025 | Tax withholding | −120,900 | $1.71 | $206.74K | 184,481 |
| Sandesh Seth Chief Executive Officer, Director | Aug 17, 2022 | Award | +300,000 | – | – | 305,381 |
| Mark Stanley Berger Chief Medical Officer | Mar 5, 2019 | Option exercise | +3,500 | $0.60 | $2.10K | 22,500 |
| Sandesh Seth Chairman & CEO, Director | Feb 21, 2019 | Option exercise | +8,125 | $0.60 | $4.88K | 161,458 |
| Sandesh Seth Chairman & CEO, Director | Dec 10, 2018 | Buy | +10,000 | $0.44 | $4.40K | 153,333 |
| Steve O'Loughlin Principal Financial Officer | Dec 10, 2018 | Buy | +10,000 | $0.44 | $4.40K | 35,500 |
| Dale L. Ludwig Chief Scientific Officer | Nov 19, 2018 | Buy | +10,000 | $0.45 | $4.50K | 10,000 |
| Sandesh Seth CEO, Director | Jul 17, 2018 | Buy | +10,000 | $0.79 | $7.90K | 143,333 |
| Steve O'Loughlin Principal Financial Officer | Jun 15, 2018 | Buy | +12,000 | $0.50 | $6.00K | 25,500 |
| Sandesh Seth Chairman & CEO, Director | Apr 19, 2018 | Buy | +5,000 | $0.38 | $1.90K | 133,333 |
| Mark Stanley Berger Chief Medical Officer | Mar 6, 2018 | Other | +14,000 | $0.50 | $7.00K | 19,000 |
| Nitya G. Ray Executive VP | Mar 6, 2018 | Other | +10,000 | $0.50 | $5.00K | 20,000 |
| Richard I. Steinhart Director | Mar 6, 2018 | Other | +7,000 | $0.50 | $3.50K | 9,500 |
| Steve O'Loughlin Principal Financial Officer | Mar 6, 2018 | Other | +10,000 | $0.50 | $5.00K | 13,500 |
| Sandesh Seth Chairman & CEO, Director | Mar 6, 2018 | Other | +52,500 | $0.50 | $26.25K | 128,333 |
| Ajit Shetty Director | Feb 28, 2018 | Buy | +22,730 | $0.43 | $9.77K | 22,730 |
| Nitya G. Ray Executive Vice President | Aug 2, 2017 | Buy | +10,000 | $0.75 | $7.50K | 10,000 |
| Sandesh Seth Chairman & CEO, Director | Aug 2, 2017 | Buy | +33,333 | $0.75 | $25.00K | 75,833 |
| Sandesh Seth Chairman and CEO, Director | Jun 15, 2017 | Buy | +2,500 | $1.17 | $2.93K | 37,500 |
| Sandesh Seth Chairman and CEO, Director | Jun 15, 2017 | Buy | +5,000 | $1.16 | $5.80K | 42,500 |
| Steve O'Loughlin Principal Financial Officer | Jun 15, 2017 | Buy | +3,500 | $1.17 | $4.10K | 3,500 |
| Mark Stanley Berger Chief Medical Officer | Jun 15, 2017 | Buy | +5,000 | $1.11 | $5.55K | 5,000 |
| Sandesh Seth Executive Chairman, Director | Dec 30, 2016 | Buy | +5,000 | $0.88 | $4.40K | 35,000 |
| Sandesh Seth Executive Chairman, Director | Dec 12, 2016 | Buy | +5,000 | $0.98 | $4.90K | 30,000 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −14,165 | $1.87 | $26.49K | 4,709,561 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −40,200 | $1.85 | $74.37K | 4,733,526 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −15,000 | $1.84 | $27.60K | 4,773,726 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −800 | $1.83 | $1.46K | 4,788,726 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −25,188 | $1.80 | $45.34K | 4,821,226 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −6,400 | $1.81 | $11.58K | 4,814,826 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −200 | $1.82 | $364 | 4,814,626 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −25,100 | $1.82 | $45.68K | 4,789,526 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 31, 2016 | Sale | −9,800 | $1.86 | $18.23K | 4,723,726 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 30, 2016 | Sale | −1,500 | $1.81 | $2.72K | 4,877,488 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 30, 2016 | Sale | −23,500 | $1.80 | $42.30K | 4,878,988 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 30, 2016 | Sale | −30,474 | $1.81 | $55.16K | 4,847,014 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 30, 2016 | Sale | −200 | $1.81 | $362 | 4,846,814 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 30, 2016 | Sale | −300 | $1.82 | $546 | 4,846,514 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 30, 2016 | Sale | −100 | $1.82 | $182 | 4,846,414 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 29, 2016 | Sale | −12,500 | $1.71 | $21.38K | 4,914,988 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 29, 2016 | Sale | −12,500 | $1.72 | $21.50K | 4,902,488 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 26, 2016 | Sale | −12,002 | $1.71 | $20.52K | 4,927,488 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 26, 2016 | Sale | −12,998 | $1.70 | $22.10K | 4,939,490 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 16, 2016 | Sale | −400 | $1.73 | $692 | 4,952,488 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 16, 2016 | Sale | −4,629 | $1.72 | $7.96K | 4,952,888 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Aug 15, 2016 | Sale | −4,439 | $1.72 | $7.64K | 4,957,517 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Jul 12, 2016 | Sale | −100 | $1.81 | $181 | 4,961,956 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Jul 12, 2016 | Sale | −3,000 | $1.80 | $5.40K | 4,962,056 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Jul 11, 2016 | Sale | −800 | $1.80 | $1.44K | 4,965,056 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Jul 8, 2016 | Sale | −21,190 | $1.80 | $38.14K | 4,965,856 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Jul 6, 2016 | Sale | −10,500 | $1.80 | $18.90K | 4,987,046 |
| Sloan-Kettering Cancer Center Memorial 10% owner | Jul 5, 2016 | Sale | −4,340 | $1.83 | $7.94K | 4,997,546 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Actinium Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,034 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?